CLINICAL_TRIALS
ClinicalTrials.gov record update
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04629703
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:37.450778+00:00
- Published At
- 2023-08-18T00:00:00+00:00
- Record Updated At
- 2023-08-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS Pneumonia", "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere", "Pneumonia", "Pneumonia, Viral"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-18"- protocolSection.identificationModule.nctId
"NCT04629703"- protocolSection.identificationModule.officialTitle
"Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.